Laura Formentini1,2,3, Alexander J Ryan4,5,6, Manuel Gálvez-Santisteban5, Leslie Carter4, Pam Taub4,7, John D Lapek8, David J Gonzalez8, Francisco Villarreal5, Theodore P Ciaraldi4,5, José M Cuezva9, Robert R Henry4,5. 1. VA San Diego Healthcare System, San Diego, CA, USA. lformentini@cbm.csic.es. 2. Departamento de Biología Molecular, CIBER Enfermedades Raras, Centro de Biología Molecular 'Severo Ochoa' (CBMSO), c/ Nicolás Cabrera 1, Universidad Autónoma de Madrid, 28049, Madrid, Spain. lformentini@cbm.csic.es. 3. Department of Medicine, University of California, San Diego, La Jolla, CA, USA. lformentini@cbm.csic.es. 4. VA San Diego Healthcare System, San Diego, CA, USA. 5. Department of Medicine, University of California, San Diego, La Jolla, CA, USA. 6. Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. 7. Department of Cardiology, University of California, San Diego, La Jolla, CA, USA. 8. Department of Pharmacology and Pharmacy, University of California, San Diego, La Jolla, CA, USA. 9. Departamento de Biología Molecular, CIBER Enfermedades Raras, Centro de Biología Molecular 'Severo Ochoa' (CBMSO), c/ Nicolás Cabrera 1, Universidad Autónoma de Madrid, 28049, Madrid, Spain.
Abstract
AIMS/HYPOTHESIS: Mitochondria are important regulators of the metabolic phenotype in type 2 diabetes. A key factor in mitochondrial physiology is the H+-ATP synthase. The expression and activity of its physiological inhibitor, ATPase inhibitory factor 1 (IF1), controls tissue homeostasis, metabolic reprogramming and signalling. We aimed to characterise the putative role of IF1 in mediating skeletal muscle metabolism in obesity and diabetes. METHODS: We examined the 'mitochondrial signature' of obesity and type 2 diabetes in a cohort of 100 metabolically characterised human skeletal muscle biopsy samples. The expression and activity of H+-ATP synthase, IF1 and key mitochondrial proteins were characterised, including their association with BMI, fasting plasma insulin, fasting plasma glucose and HOMA-IR. IF1 was also overexpressed in primary cultures of human myotubes derived from the same biopsies to unveil the possible role played by the pathological inhibition of the H+-ATP synthase in skeletal muscle. RESULTS: The results indicate that type 2 diabetes and obesity act via different mechanisms to impair H+-ATP synthase activity in human skeletal muscle (76% reduction in its catalytic subunit vs 280% increase in IF1 expression, respectively) and unveil a new pathway by which IF1 influences lipid metabolism. Mechanistically, IF1 altered cellular levels of α-ketoglutarate and L-carnitine metabolism in the myotubes of obese (84% of control) and diabetic (76% of control) individuals, leading to limited β-oxidation of fatty acids (60% of control) and their cytosolic accumulation (164% of control). These events led to enhanced release of TNF-α (10 ± 2 pg/ml, 27 ± 5 pg/ml and 35 ± 4 pg/ml in control, obese and type 2 diabetic participants, respectively), which probably contributes to an insulin resistant phenotype. CONCLUSIONS/ INTERPRETATION: Overall, our data highlight IF1 as a novel regulator of lipid metabolism and metabolic disorders, and a possible target for therapeutic intervention.
AIMS/HYPOTHESIS: Mitochondria are important regulators of the metabolic phenotype in type 2 diabetes. A key factor in mitochondrial physiology is the H+-ATP synthase. The expression and activity of its physiological inhibitor, ATPase inhibitory factor 1 (IF1), controls tissue homeostasis, metabolic reprogramming and signalling. We aimed to characterise the putative role of IF1 in mediating skeletal muscle metabolism in obesity and diabetes. METHODS: We examined the 'mitochondrial signature' of obesity and type 2 diabetes in a cohort of 100 metabolically characterised human skeletal muscle biopsy samples. The expression and activity of H+-ATP synthase, IF1 and key mitochondrial proteins were characterised, including their association with BMI, fasting plasma insulin, fasting plasma glucose and HOMA-IR. IF1 was also overexpressed in primary cultures of human myotubes derived from the same biopsies to unveil the possible role played by the pathological inhibition of the H+-ATP synthase in skeletal muscle. RESULTS: The results indicate that type 2 diabetes and obesity act via different mechanisms to impair H+-ATP synthase activity in human skeletal muscle (76% reduction in its catalytic subunit vs 280% increase in IF1 expression, respectively) and unveil a new pathway by which IF1 influences lipid metabolism. Mechanistically, IF1 altered cellular levels of α-ketoglutarate and L-carnitine metabolism in the myotubes of obese (84% of control) and diabetic (76% of control) individuals, leading to limited β-oxidation of fatty acids (60% of control) and their cytosolic accumulation (164% of control). These events led to enhanced release of TNF-α (10 ± 2 pg/ml, 27 ± 5 pg/ml and 35 ± 4 pg/ml in control, obese and type 2 diabeticparticipants, respectively), which probably contributes to an insulin resistant phenotype. CONCLUSIONS/ INTERPRETATION: Overall, our data highlight IF1 as a novel regulator of lipid metabolism and metabolic disorders, and a possible target for therapeutic intervention.
Entities:
Keywords:
Energy metabolism; H+-ATP synthase; Inhibitory factor 1 (IF1); Mitochondria; Obesity; Skeletal muscle; Type 2 diabetes
Authors: Kurt Højlund; Krzysztof Wrzesinski; Peter Mose Larsen; Stephen J Fey; Peter Roepstorff; Aase Handberg; Flemming Dela; Jørgen Vinten; James G McCormack; Christine Reynet; Henning Beck-Nielsen Journal: J Biol Chem Date: 2003-01-16 Impact factor: 5.157
Authors: Denis V Titov; Valentin Cracan; Russell P Goodman; Jun Peng; Zenon Grabarek; Vamsi K Mootha Journal: Science Date: 2016-04-07 Impact factor: 47.728
Authors: M Lorenzo; S Fernández-Veledo; R Vila-Bedmar; L Garcia-Guerra; C De Alvaro; I Nieto-Vazquez Journal: J Anim Sci Date: 2007-10-16 Impact factor: 3.159
Authors: Craig S Stump; Kevin R Short; Maureen L Bigelow; Jill M Schimke; K Sreekumaran Nair Journal: Proc Natl Acad Sci U S A Date: 2003-06-13 Impact factor: 11.205
Authors: Fulvio Santacatterina; Laura Sánchez-Cenizo; Laura Formentini; Maysa A Mobasher; Estela Casas; Carlos B Rueda; Inmaculada Martínez-Reyes; Cristina Núñez de Arenas; Javier García-Bermúdez; Juan M Zapata; María Sánchez-Aragó; Jorgina Satrústegui; Ángela M Valverde; José M Cuezva Journal: Oncotarget Date: 2016-01-05
Authors: Katon A Kras; Paul R Langlais; Nyssa Hoffman; Lori R Roust; Tonya R Benjamin; Elena A De Filippis; Valentin Dinu; Christos S Katsanos Journal: Metabolism Date: 2018-09-22 Impact factor: 8.694
Authors: Andrya J Durr; Quincy A Hathaway; Amina Kunovac; Andrew D Taylor; Mark V Pinti; Saira Rizwan; Danielle L Shepherd; Chris C Cook; Garrett K Fink; John M Hollander Journal: Am J Physiol Cell Physiol Date: 2022-02-02 Impact factor: 4.249
Authors: Birgitta W van der Kolk; Sina Saari; Alen Lovric; Muhammad Arif; Marcus Alvarez; Arthur Ko; Zong Miao; Navid Sahebekhtiari; Maheswary Muniandy; Sini Heinonen; Ali Oghabian; Riikka Jokinen; Sakari Jukarainen; Antti Hakkarainen; Jesper Lundbom; Juho Kuula; Per-Henrik Groop; Taru Tukiainen; Nina Lundbom; Aila Rissanen; Jaakko Kaprio; Evan G Williams; Nicola Zamboni; Adil Mardinoglu; Päivi Pajukanta; Kirsi H Pietiläinen Journal: Cell Rep Med Date: 2021-03-30
Authors: Cristina Sánchez-González; Cristina Nuevo-Tapioles; Juan Cruz Herrero Martín; Marta P Pereira; Sandra Serrano Sanz; Ana Ramírez de Molina; José M Cuezva; Laura Formentini Journal: EMBO J Date: 2020-06-03 Impact factor: 11.598